NCT00471367View on ClinicalTrials.gov

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

PHASE1TerminatedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

April 30, 2007

Study Completion Date

December 31, 2008

Conditions

LymphomaNHLNon-Hodgkin Lymphoma

Interventions

DRUG

AZD4877

intravenous infusion administered twice a week for 2 weeks

Trial Locations (3)

Unknown

Research Site, New York

Research Site, Philadelphia

Research Site, Greenville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY